VIVUS, Inc. (VVUS) Pops as Larger Qsymia Retail Presence Expected Soon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Brean Capital Maintains Sell of Vivus (VVUS), Notes Slower April Growth
May 8, 2013 3:06 PM EDTBrean Capital today maintained a Sell rating on Vivus (NASDAQ: VVUS) with a price target of $6.00. Vivus recently reported Q1 results.
Commenting, analyst Jonathan Aschoff said, "A total of 59,000 prescriptions were sold in 1Q13, of which 21,000 were shipped under the free trial offer,... More
VIVUS, Inc. (VVUS) Posts Q1 Loss of 53c/Share
May 8, 2013 7:31 AM EDTVIVUS, Inc. (NASDAQ: VVUS) reported Q1 EPS of ($0.53), $0.02 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $5.22 million.
For earnings history and earnings-related data on VIVUS, Inc. (VVUS) click here.... More
